Survival for children and young adults with high-risk B-acute lymphoblastic leukemia has improved significantly, but 20% to 25% of patients are not cured. Children's Oncology Group study AALL0232 tested two interventions to improve survival.
Patients and Methods
Between January 2004 and January 2011, AALL0232 enrolled 3,154 participants 1 to 30 years old with newly diagnosed high-risk B-acute lymphoblastic leukemia. By using a 2 3 2 factorial design, 2,914 participants were randomly assigned to receive dexamethasone (14 days) versus prednisone (28 days) during induction and high-dose methotrexate versus Capizzi escalating-dose methotrexate plus pegaspargase during interim maintenance 1.
Results
Planned interim monitoring showed the superiority of the high-dose methotrexate regimens, which exceeded the predefined boundary and led to cessation of enrollment in January 2011. At that time, participants randomly assigned to high-dose methotrexate during interim maintenance 1 versus those randomly assigned to Capizzi methotrexate had a 5-year event-free survival (EFS) of 82% versus 75.4% (P = .006). Mature final data showed 5-year EFS rates of 79.6% for high-dose methotrexate and 75.2% for Capizzi methotrexate (P = .008). High-dose methotrexate decreased both marrow and CNS recurrences. Patients 1 to 9 years old who received dexamethasone and highdose methotrexate had a superior outcome compared with those who received the other three regimens (5- year EFS, 91.2% v 83.2%, 80.8%, and 82.1%; P = .015). Older participants derived no benefit from dexamethasone during induction and experienced excess rates of osteonecrosis.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and a major cause of cancer death before age 40 years. Approximately 85% of pediatric ALL cases are B-acute lymphoblastic leukemia (B-ALL), subclassified as National Cancer Institute (NCI) standard risk and high risk (HR) based on age and WBC count. 1 Clinical trials have produced incremental improvements in event-free survival (EFS) and overall survival (OS) for children with HR B-ALL 2 through intensification of postinduction therapy and more accurate risk stratification. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Compared with prednisolone, dexamethasone has greater cytotoxic effects on ALL cells in vitro, 14, 15 superior CNS penetration, and a longer CSF half-life. 16 In clinical trials, dexamethasone has a greater antileukemic effect than prednisone [17] [18] [19] [20] but is associated with increased toxicities, including induction death, fractures, osteonecrosis, and behavioral disturbances. [21] [22] [23] [24] Methotrexate is a critical component of ALL therapy and plays an important role in CNS prophylaxis. Worldwide, two different methotrexate intensification strategies have been studied: Highdose methotrexate (HD-MTX) regimens of 2 to 5 g/m 2 administered over 24 hours followed by leucovorin rescue 5, 6, 26 and the Capizzi regimen with lower, escalating doses of intravenous methotrexate (C-MTX) of 100 to 300 mg/m 2 through short infusions, without leucovorin rescue, followed by asparaginase. 3, 4 Both strategies are effective, but they have never been directly compared in childhood ALL. Children's Oncology Group (COG) AALL0232 tested the safety and efficacy of dexamethasone versus prednisone during induction and HD-MTX with leucovorin rescue versus C-MTX plus pegaspargase during interim maintenance 1.
PATIENTS AND METHODS

Patient Characteristics
AALL0232 enrolled participants between January 2004 and January 2011. Patients with newly diagnosed B-ALL age 1 to 9 years with initial WBC $ 50,000/mL or 10 to 30 years with any WBC were eligible. The diagnosis was determined by morphologic, biochemical, and immunologic features. 3, 4 CNS status was defined based on CSF obtained before therapy as follows: CNS1 (no blasts), CNS2 (CSF WBC , 5/mL with blasts), or CNS3 (CSF WBC $ 5/mL with blasts and/or clinical signs of CNS leukemia). AALL0232 was approved by NCI and the institutional review boards of participating institutions. Informed consent was obtained from participants or a parent/guardian in accordance with Department of Health and Human Services guidelines.
Treatment
AALL0232 used a 2 3 2 factorial design with a COG-modified augmented intensity Berlin-Frankfurt-Münster backbone. 3 Eligible participants were randomly assigned at study entry to receive dexamethasone (10 mg/m 2 /day) on days 1 to 14 versus prednisone (60 mg/m 2 /day) on days 1 to 28 during induction and HD-MTX versus C-MTX during interim maintenance 1. Treatment regimens PC, PH, DC, and DH were designated by the corticosteroid (prednisone [P], dexamethasone [D]) and methotrexate (Capizzi [C], high dose [H]) assignments. Early response was used to refine treatment.
Rapid early responders (RERs) had an M1 marrow (, 5% blasts) by induction day 15 and , 0.1% minimal residual disease (MRD) in the day 29 marrow by flow cytometry. 28 Slow early responders (SERs) had an M1 marrow on induction day 29 but with either an M2 (5% to 25% blasts) or M3 (. 25% blasts) marrow on induction day 15 or MRD $ 0.1% on day 29 marrow. They received a second interim maintenance with C-MTX, a second delayed intensification, and 12-Gy cranial irradiation. Patients with an M2 marrow or $ 1% MRD at day 29 received 2 additional weeks of induction therapy and were considered SERs if their day 43 marrow was M1 with , 1% MRD; otherwise, they were considered induction failures and removed from protocol therapy, as were those with an M3 marrow at day 29. Patients with CNS3 status were nonrandomly assigned to receive HD-MTX and 18-Gy cranial irradiation. Those with testicular leukemia at diagnosis and those who received . 48 hours of corticosteroid therapy in the week before diagnosis participated in the induction corticosteroid random assignment but were nonrandomly assigned to HD-MTX with two interim maintenance and delayed intensification phases. If testicular involvement was not resolved at end induction, 24-Gy testicular irradiation was given during consolidation. Patients with very-high-risk (VHR) ALL-BCR-ABL1 fusion, hypodiploidy with , 44 chromosomes, and/or DNA index , 0.81, induction failure, or SER with MLL rearrangement-were removed from protocol therapy after induction. Therapy was continued for 2 years for females and 3 years for males from the beginning of interim maintenance 1. Therapy details are provided in Appendix Table A1 (online only).
Therapy amendments were made during the conduct of AALL0232. Patients with Down syndrome were initially eligible, and 44 were randomly assigned between the DC and PC treatment regimens, but this group experienced excessive toxic mortality and were made ineligible for enrollment in 2006. An increased incidence of osteonecrosis was observed in children 10 years of age and older assigned to dexamethasone during induction. Consequently, AALL0232 was amended in 2008 to exclude patients 10 years of age and older from the corticosteroid assignment. Additionally, all subsequently received discontinuous dexamethasone during delayed intensification and prednisone during maintenance.
Toxicity Assessment
Data on adverse events and clinically significant laboratory findings were collected using the NCI Common Terminology Criteria for Adverse Events version 3.0 until December 2010 and version 4.0 thereafter. Adverse event reporting was supplemented with the NCI Adverse Event Expedited Reporting System and MedWatch reports.
Statistical Analysis
The study was originally designed as a 2 3 2 randomized factorial design, with the first factor comparing the induction corticosteroid (prednisone versus dexamethasone) and the second comparing methotrexate approaches (HD-MTX versus C-MTX) during interim maintenance 1. Random assignment occurred at study entry. Power calculations are based on log-rank test, with 10 planned interim analyses monitoring for efficacy. Two-sided log-rank tests were to be used for EFS comparisons.
Interim monitoring in January 2011 revealed that the predefined efficacy monitoring boundary had been crossed by showing increased efficacy for HD-MTX compared with C-MTX, which led to early closure of accrual. All patient assigned to C-MTX who had not yet finished the first cycle of maintenance therapy crossed over to the HD-MTX regimen.
EFS was defined as the time from study entry to first event (induction failure, induction death, relapse, second malignancy, remission death) or date of last follow-up for event-free patients. Those who crossed over to the HD-MTX arm were censored at the time of crossover. OS was defined as the time from study entry to death or date of last follow-up. Survival rates were estimated by using the Kaplan-Meier method with standard errors. 29,30 Survival curves were compared by using the log-rank test. Cumulative incidence rates between regimens were computed by using the cumulative incidence function for competing risks, and comparisons were conducted with the K-sample test. 31 P , .05 was considered significant for all comparisons. All analyses were performed with SAS software (version 9.4; SAS Institute, Cary, NC). Graphics were generated with R version 2.13.1 (http://www.r-project.org).
RESULTS
Participants
AALL0232 enrolled 3,154 participants-48 were ineligible; 44 had Down syndrome; and 148 were nonrandomly assigned to specific regimens due to CNS3 status, testicular involvement, or extensive corticosteroid pretreatment (Fig 1) . The remaining 2,914 participants were randomly assigned to the four treatment regimens-PC (n = 926), PH (n = 926), DC (n = 535), DH (n = 527). Randomly assigned participants with VHR ALL features-BCR-ABL1 (n = 135), hypodiploidy (n = 81), MLL rearrangement with SER (n = 24)-were removed from protocol therapy after induction and are excluded from this report. Of the randomly assigned participants with complete data at the end of induction (n = 2,554), 80.3% were classified as RERs (n = 2,051) and 19.7% were classified as SERs (n = 503). These include 35 RERs and 111 SERs classified as induction failures or induction deaths.
Age distribution ranged from 12 months to 30 years, with 33% 1 to 9 years old, 47% 10 to 15 years old, and 20% 16 to 30 years old, including 2% age 21 years and older. Fifty-four percent were male and 46% female. African American enrollment was 6.7%, and Hispanic enrollment was 23.8%. The presenting WBC distribution was 37.6% , 10,000/mL, 18.9% 10 to 49,999/mL, 23.9% 50 to 99,999/mL, 12.6% 100 to 199,999/mL, and 7.0% $ 200,000/mL. The distribution of CNS status at entry was 85.9% CNS1 and 14.1% CNS2 for the randomized cohort.
Treatment Outcome
The 5-year EFS and OS for the 2,979 participants eligible and evaluable for postinduction therapy was 75.2 6 1.1% and 85.0 6 0.9%, respectively (Fig 2A) . For the 2,573 participants considered in the evaluation of the randomized questions (eligible, evaluable for postinduction therapy, not VHR, and not Down syndrome), the 5-year EFS was 77.5 6 1.2%, and OS was 87.5 6 0.9% ( Fig 2B) . As expected, RERs had better 5-year EFS (83.9 6 1.1% v 53.3 6 3.1%, P ,.001; Appendix Fig A1A) and OS (91.3 6 0.9% v 74.3 6 2.8%, P , .001; Appendix Fig A1B) than SERs.
Methotrexate Random Assignment
Interim monitoring in January 2011 showed that the predefined efficacy monitoring boundary had been crossed, with superior outcomes for participants assigned to HD-MTX versus C-MTX, and AALL0232 accrual was halted. At that time, the estimated 5-year EFS rates were 82 6 3.4% (HD-MTX) versus 75.4 6 3.6% (C-MTX; P = .006). Therapy changes were recommended to provide HD-MTX to all participants who had not yet completed course 1 of maintenance or received cranial irradiation. For the final analyses, the outcome of those assigned to C-MTX who subsequently received HD-MTX was censored at the time of therapy crossover (n = 127). These analyses showed 5-year EFS rates of 79.6 6 1.6% for the HD-MTX regimens versus 75.2 6 1.7% for the C-MTX regimens (P = .008; Fig 3A) and 5-year OS rates of 88.9 6 1.2% for HD-MTX and 86.1 6 1.4% for C-MTX (P = .025; Appendix Fig A2A) . For RERs, the 5-year EFS rates were 84.9 6 1.6% for HD-MTX versus 82.8 6 1.7% for C-MTX (P = .202; Fig 3B) , and OS rates were 91.8 6 1.2% versus 90.7 6 1.3% (P = .531; Appendix Fig A2B) . For SERs, the 5-year EFS rates were 57.8 6 4.6% for HD-MTX and 49.4 6 4.2% for C-MTX (P = .095; Fig 3C) , and OS rates were 77.9 6 3.8% versus 71.2 6 3.9% (P = .048; Appendix Fig A2C) . For patients 10 years of age and older nonrandomly assigned to receive prednisone during induction after April 2008, those randomly assigned to receive HD MTX had a nonsignificant trend towards improved outcome (4-year EFS 79.1% v 77% with C-MTX; P = .569; Figure A4 ). Five-year www.jco.org cumulative incidence rates for HD-MTX versus C-MTX were 7.0 6 0.8% and 8.6 6 0.9% for marrow relapse (P = .089), 2.9 6 0.5% versus 4.1 6 0.6% for CNS relapse (P = .09), and 2.0 6 0.4% versus 2.1 6 0.4% for remission deaths (P = .89). Table 1 provides the raw number of events by methotrexate regimen.
Corticosteroid Random Assignment
Participants 1 to 9 years of age (n = 851) were randomly assigned to the corticosteroid and methotrexate regimens-DH (n = 206), DC (n = 218), PH (n = 213), PC (n = 214). Because there was a significant qualitative interaction between the corticosteroid and methotrexate assignments (P = .048), EFS comparisons were made among the four regimens. The DH regimen was superior, with a 5-year EFS rate of 91.2 6 2.8% compared with 83.2 6 3.4% (DC), 80.8 6 3.7% (PH), and 82.1 6 3.5% (PC; P = .015; Fig 4A) and a nonsignificant trend toward improved 5-year OS (P = .444; Appendix Fig A3A) . Five-year cumulative incidence rates for the four regimens were 3.2 6 1.3% (DH), 7.3 6 2.0% (DC), 3.5 6 1.4% (PH), and 4.8 6 1.7% (PC) for marrow relapse (P = .024) and 2.0 6 1.0% (DH), 4.9 6 1.5% (DC), 5.0 6 1.6% (PH), and 5.4 6 1.6% (PC) for CNS relapse (P = .28).
Before June 2008, when the induction corticosteroid random assignment was closed to older patients due to excess rates of osteonecrosis with dexamethasone, 1,048 participants 10 years of age and older were randomly assigned to dexamethasone (n = 523) and prednisone (n = 525). The 5-year EFS rates for the older participants were virtually identical at 73.1 6 2.1% (dexamethasone) and 73.9 6 2.2% (prednisone; P = .78; Fig 4B) as were 5-year OS rates (P = .97; Appendix Fig A3B) . Appendix Table A2 provides the raw number of events by corticosteroid regimen.
Toxicity
Nonrelapse mortality. Among the 3,106 eligible and evaluable participants, 104 experienced death as a first event, with 53 (1.7%) induction deaths and 51 (1.7%) remission deaths. Among all eligible, evaluable, randomly assigned participants (n = 2,573), 97 experienced death as a first event, with 48 (1.9%) induction deaths and 49 (1.9%) remission deaths. Induction deaths occurred in 1.7% (18 of 1,062) participants assigned to dexamethasone and 1.7% (30 of 1,852) of those assigned to prednisone. The 5-year cumulative incidence rate for remission deaths was 2.0 6 0.3%. The 5-year cumulative incidence rates of remission deaths among all randomly assigned participants were as follows: DC, 1.8 6 0.6%; DH, 1.4 6 0.6%; PC, 2.3 6 0.6%; and PH, 2.3 6 0.6% (P = .77). The higher rates observed on the prednisone induction arms are due to nonrandom assignment of older patients to these arms after 2008.
Methotrexate random assignment. There was a higher rate of febrile neutropenia during interim maintenance 1 in the C-MTX regimens (8.3% v 5.1% with HD-MTX; P = .003; Table 2 ). Ischemic cerebrovascular toxicity was observed in five patients who received HD-MTX, whereas no patients who received C-MTX had this toxicity (P =.03). No other statistically significant differences were found in toxicity between the methotrexate regimens during interim maintenance 1, including mucositis, neurotoxicity, osteonecrosis, and death in remission.
Corticosteroid random assignment. During induction, dexamethasone was associated with higher rates of febrile neutropenia (18.2% v 11.0% with prednisone; P , .001) and infections/ infestations (29.4% v 20.3% with prednisone; P ,.001; Table 2 ). Despite higher rates of infection on the dexamethasone arms, there was no difference in the induction death rate compared with the prednisone regimens (18 of 946 [1.9%] v 17 of 952 [1.8%] with dexamethasone and prednisone, respectively; P = .87). Among patients younger than 10 years of age, induction deaths were three of 424 (0.71%) for dexamethasone and four of 427 (0.94%) for prednisone (P = .71). For those 10 years of age and older, induction deaths occurred in 15 of 522 (2.9%) assigned to dexamethasone versus 13 of 525 (2.5%) assigned to prednisone (P = .69). Among patients 10 years of age and older who participated in the induction corticosteroid arm before it was closed in 2008, the 5-year cumulative incidence of osteonecrosis was 24.3 6 2.3% for those assigned to 14 days of dexamethasone and 15.9 6 2.0% for those assigned to 28 days of prednisone (P = .001). There were no other significant differences in toxicities during induction between the two corticosteroid regimens.
DISCUSSION
Survival for children and young adults with HR-ALL has improved over time due to more precise risk stratification and refinement of postinduction therapy through serial clinical trials. 2, 5, [8] [9] [10] [11] [12] [13] AALL0232 improved survival further for these patients and has changed clinical practice in North America.
Methotrexate Random Assignment
Intravenous methotrexate is a key component of ALL postinduction intensification strategies. When this study was undertaken, the COG used escalating C-MTX without leucovorin rescue plus asparaginase and vincristine, whereas most other groups used HD-MTX plus leucovorin rescue with mercaptopurine with similar outcomes. However, the impact of the HD-MTX regimen remained uncertain. AALL0232 establishes that the HD-MTX regimen is superior to C-MTX for the treatment of HR B-ALL, with mature data showing significant improvements in both 5-year EFS Probability EFS (80% v 75%; P = .008) and OS (88.9 6 1.2% v 86.1 6 1.4%; P = .025) rates. The improved outcome associated with HD-MTX occurred in all subgroups analyzed, was due to decreased rates of both marrow and CNS relapse, and was especially evident in SERs. In contrast to RERs, all SERs received a second interim maintenance phase with C-MTX. AALL0232 cannot be considered a direct comparison of methotrexate doses and schedules alone because each regimen contained additional agents (eg, 6-mercaptoputine in HD-MTX, pegaspargase in C-MTX).
Close monitoring revealed no statistically significant difference in occurrence of mucositis, neurotoxicity, osteonecrosis, or other toxicities, including death, during remission between the methotrexate regimens during interim maintenance 1. C-MTX was associated with a greater frequency of febrile neutropenia than HD-MTX (8.3% v 5.1%; P = .003). This may be due to the myelosuppressive effects of MTX given without leucovorin rescue or to the additive myelosuppressive effect of asparaginase. 32 Ischemic cerebrovascular toxicity was observed in five patients who received HD-MTX compared with none who received C-MTX. Although this reached statistical significance, the small numbers preclude any definite conclusion on the clinical significance of these observations. On the basis of these findings, we conclude that HD-MTX is both efficacious and safe and should be the standard of care during interim maintenance for children and adolescents with HR B-ALL.
Corticosteroid Random Assignment
Prior studies showed that dexamethasone had greater antileukemic activity compared with prednisone but was also associated with higher rates of several toxicities. [17] [18] [19] [20] [21] [22] [23] [24] Due to concern for serious acute infectious toxicity associated with 4 weeks of dexamethasone combined with an anthracycline in a four-drug ALL induction, AALL0232 compared dexamethasone 10 mg/m 2 /day for 14 days to 60 mg/m 2 /day of prednisone for 28 days. Participants assigned to dexamethasone experienced higher rates of febrile neutropenia and infections than those assigned to prednisone; however, no significant difference in induction deaths was found. Of note, the brief, but continuous exposure to dexamethasone during induction contributed to a higher rate of subsequent osteonecrosis compared with participants assigned to prednisone (24.3% v 15.9%; P = .001) 10 years of age or older. This finding led to the termination of the corticosteroid assignment for patients 10 years and older in 2008. With consideration of the relative efficacy and toxicity of the corticosteroid regimens, AALL0232 establishes that children and adolescents 10 years of age or older with HR B-ALL should receive 28 days of prednisone during induction.
EFS Probability
Because there was a statistical interaction between the corticosteroid and methotrexate assignments, a direct comparison between dexamethasone and prednisone is not possible in the patients younger than 10 years. Comparison of the four regimens demonstrated a statistically significant improvement in EFS and a trend toward improved OS with DH compared with the other three regimens DC, PH, and PC. On the basis of this result, AALL0232 has established a new standard of care for patients 1 to 9 years old with HR B-ALL, who should receive 14 days of dexamethasone during induction and HD-MTX during interim maintenance 1. Dexamethasone intriguingly had more antileukemic efficacy than prednisone in younger patients, but no difference was seen among those 10 years and older. This observation may be due to age-related differences in corticosteroid pharmacokinetics. Younger patients have more rapid clearance of dexamethasone, and hence dexamethasone, a more potent corticosteroid, may enhance the impact of corticosteroid differences in this population. 33, 34 In contrast, older patients have slower clearance of corticosteroids, which might minimize any improvement in efficacy while contributing to an increase in bone toxicity with dexamethasone.
In conclusion, over the past 50 years, the dramatic improvement in survival for children with ALL has been a direct result of serial clinical trials conducted worldwide. The key strategies that have led to this success have been more accurate risk stratification, prophylactic treatment of the CNS, and refinement of postinduction intensification. Given the high survival of children with ALL, there have been concerns about whether outcome has reached a plateau. COG AALL0232 has demonstrated that optimization of conventional chemotherapy agents remains a viable strategy by showing superior outcome with HD-MTX for all patients with HR B-ALL as does 14 days of dexamethasone during induction for patients 1 to 9 years of age. It is likely that continued improvements in the treatment of children, adolescents, and young adults with B-ALL will derive from both further refinements in the use of conventional agents and application of targeted therapies based on novel genomic discoveries. 35 
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